Tumor antigen presentation by autologous dendritic cell

The term "Tumor antigen presentation by autologous dendritic cells" refers to an immunotherapeutic strategy rather than a single molecular target. In this approach, dendritic cells—potent professional antigen-presenting cells—are isolated from the patient (autologous), loaded ex vivo with antigens derived from the patient's own tumor tissue or lysate, matured under controlled conditions, and then re-infused into the patient as a personalized cancer vaccine. These modified DCs present processed tumor antigens on their surface MHC molecules to activate naïve or memory T-cells—primarily cytotoxic CD8+ lymphocytes—which can then recognize and destroy cancer cells expressing those same antigens in vivo[2][4][6]. This method leverages the natural ability of DCs to bridge innate and adaptive immunity through efficient priming of anti-tumor responses. While clinical studies have shown that such vaccines are generally well tolerated with some evidence for durable immune responses in cancers like melanoma, glioblastoma, ovarian carcinoma, hepatocellular carcinoma, and renal cell carcinoma,[2] overall efficacy has been limited by factors such as poor migration or maturation of ex vivo-generated DCs,[4] heterogeneity among DC subsets,[6] challenges in generating sufficient numbers of potent cross-presenting cDC1-type DCs,[4] as well as suppression within the tumor microenvironment that impairs effective immune activation.[3] This entry is not a canonical molecular target like an enzyme or receptor but describes a therapeutic modality based on cellular function. Therefore it should be flagged as incorrect if used where only discrete protein/gene targets are appropriate. Note: This entry does not correspond to a single molecule/receptor but rather describes an immunotherapy technique involving whole-cell manipulation. For structured databases focused on druggable targets at the gene/protein level (e.g., kinases, GPCRs), this would be considered non-standard/inaccurate usage.

Other names

Dendritic cell-based tumor antigen presentationAutologous dendritic cell vaccineDC-based cancer immunotherapyTumor antigen-loaded dendritic cells

Presentation of tumor antigens to T-cells via MHC class I/II pathways by autologous dendritic cells, leading to activation of cytotoxic T lymphocytes and helper T-cells against tumor cells[1][2][6].